Investor Presentation First Nine Months of 2022

37 B-cell function Investor presentation First nine months of 2022 Diabetes is a chronic disease requiring treatment intensification over time Diet and exercise OAD GLP-1 Distribution of patients and value across treatment classes 44% 4% 14% 19% 2% 9% 29% Insulin 10% 9% 28% 32% Time Patients Insulin Value GLP-1 Inj. Oral GLP-1 SGLT-2i DPP-4i Trad. OAD Note: Patient distribution across treatment classes is indicative and based on data for USA, Germany, France. Other OADS cover: metformin, sulfonylurea, thiazolidinediones. Source: IQVIA PharMetrix claims data, IQVIA disease analyser, IQVIA MIDAS; value figures based on IQVIA MAT, Aug 2022 OAD: Oral anti-diabetic Novo NordiskⓇ

View entire presentation